<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1204233533
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Uptravi 200 mcg titration pack
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SELEXIPAG
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        140
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        25496.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EXCELLA GMBH CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EXCELLA GMBH CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Janssen-Cilag International NV 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AC27
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Uptravi is a medicine that contains the active substance selexipag. It acts on blood vessels in a similar way to the natural substance prostacyclin, making them relax and widen.</p><p>&nbsp;</p><p>Uptravi is used for the long‑term treatment of pulmonary arterial hypertension (PAH) in adult patients insufficiently controlled with other types of medicines for PAH known as endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. Uptravi can be used on its own if the patient is not a candidate for these medicines.</p><p>&nbsp;</p><p>PAH is high blood pressure in the blood vessels that carry blood from the heart to the lungs (the pulmonary arteries). In people with PAH, these arteries narrow, so the heart has to work harder to pump blood through them. This may cause people to feel tired, dizzy, short of breath, or experience other symptoms.</p><p>&nbsp;</p><p>By acting in a similar way to the natural substance prostacyclin, this medicine widens the pulmonary arteries and reduces their hardening. This makes it easier for the heart to pump blood through the pulmonary arteries. Uptravi lowers the pressure in the pulmonary arteries, it relieves the symptoms of PAH and slows down progression of PAH disease.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Uptravi</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to selexipag or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a heart problem, such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poor blood flow to the heart muscles (severe coronary heart disease or unstable angina); symptoms can include chest pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack within the last 6 months</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weak heart (decompensated cardiac failure) that is not under close medical observation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe irregular heartbeat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; defect of the heart valves (inborn or acquired) that causes the heart to work poorly (not related to pulmonary hypertension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a stroke within the last 3 months, or any other occurrence that reduced the blood supply to the brain (e.g., transient ischaemic attack)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking gemfibrozil (medicine used to lower the level of fats [lipids] in the blood)</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your PAH doctor or nurse before taking Uptravi if you</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are taking medicines for high blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have low blood pressure associated with symptoms such as dizziness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have recently experienced significant blood loss or fluid loss such as severe diarrhoea or vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have problems with your thyroid gland</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe problems with your kidneys or are undergoing dialysis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have had severe problems with your liver not working properly</p><p>&nbsp;</p><p>If you notice any of the above signs or your condition changes, <strong>tell your doctor immediately</strong>.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>Do not give this medicine to children under 18&nbsp;years of age, because Uptravi has not been tested in children.</p><p>&nbsp;</p><p><strong>Elderly patients</strong></p><p>&nbsp;</p><p>There is limited experience with Uptravi in patients older than 75&nbsp;years. Uptravi should be used with caution in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and Uptravi</strong></p><p>&nbsp;</p><p>Tell your doctor if you are taking, have recently taken, or might take any other medicines.</p><p>Taking other medicines may affect how Uptravi works.</p><p>&nbsp;</p><p>Talk to your PAH doctor or nurse if you are taking any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gemfibrozil (medicine used to lower the level of fats [lipids] in the blood)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clopidogrel (medicine used to inhibit blood clots in coronary artery disease)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferasirox (medicine used to remove iron from the blood stream)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Teriflunomide (medicine used to treat relapsing-remitting multiple sclerosis)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine (medicine used to treat some forms of epilepsy, nerve pain or to help control serious mood disorders when some other medicines do not work)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin (medicine used to treat epilepsy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Valproic acid (medicine used to treat epilepsy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probenecid (medicine used to treat gout)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluconazole, rifampicin or rifapentine (antibiotics used to treat infections)</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>Uptravi is not recommended during pregnancy and breast‑feeding. If you are a woman who can have children, you should use an effective contraceptive method while taking Uptravi. If you are pregnant or breast‑feeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Uptravi can cause side effects such as headaches and low blood pressure (see section&nbsp;4), which may affect your ability to drive; the symptoms of your condition can also make you less fit to drive.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Uptravi should only be prescribed by a doctor experienced in the treatment of PAH. Always take this medicine exactly as your doctor has told you. Check with your doctor if you are in doubt or have any questions.</p><p>&nbsp;</p><p>Tell your doctor if you experience side effects, as your doctor may recommend that you change your Uptravi dose.</p><p>&nbsp;</p><p>Tell your doctor if you are taking other medicines as your doctor may recommend that you take Uptravi only once daily.</p><p>&nbsp;</p><p>If you have poor vision or experience any type of blindness, get help from another person when taking Uptravi during the titration period (process of gradually increasing your dose).</p><p>&nbsp;</p><p><strong>Finding the right dose for you</strong></p><p>&nbsp;</p><p>At the start of treatment, you will take the lowest dose. This is one 200&nbsp;microgram tablet <strong>in the morning and another 200</strong>&nbsp;<strong>microgram tablet in the evening</strong><strong>, about 12 hours apart</strong>. It is recommended to initiate treatment in the evening. Your doctor will instruct you to gradually increase your dose. This is called titration. It lets your body adjust to the new medicine. The goal of titration is to reach the most appropriate dose. This will be the highest dose you can tolerate, which may reach the maximum dose of 1,600&nbsp;micrograms in the morning and in the evening.</p><p>&nbsp;</p><p>The first pack of tablets you receive will contain the light‑yellow 200&nbsp;microgram tablets.</p><p>Your doctor will tell you to increase your dose in steps, usually every week but the interval between increases could be longer.</p><p>&nbsp;</p><p>With each step, you will add one 200&nbsp;microgram tablet to your morning dose and another 200&nbsp;microgram tablet to your evening dose. <strong>The first intake of the increased dose is recommended to be in the evening.</strong> The diagram below shows the number of tablets to take <strong>every</strong><strong> morning</strong> and <strong>every</strong><strong> evening </strong>for the first 4&nbsp;steps.</p><p>&nbsp;</p><p><img src="data:image/jpeg;base64,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" alt="" width="877" height="480" vspace="0" hspace="0" border="0" style="width:877px;height:480px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>&nbsp;</p><p>If your doctor tells you to increase your dose further, you will add one 200&nbsp;microgram tablet to your morning dose and one 200&nbsp;microgram tablet to your evening dose with each new step. The first intake of the increased dose is recommended to be in the evening.</p><p>&nbsp;</p><p>If your doctor instructs you to further increase your dose and move to step&nbsp;5, this may be done by taking one green 800&nbsp;microgram tablet and one light‑yellow 200&nbsp;microgram tablet in the morning and one 800&nbsp;microgram tablet and one 200&nbsp;microgram tablet in the evening.</p><p>&nbsp;</p><p>The maximum dose of Uptravi is 1,600&nbsp;micrograms in the morning and 1,600&nbsp;micrograms in the evening. However, not every patient will reach this dose, because different patients require different doses.</p><p>&nbsp;</p><p>The diagram below shows the number of tablets to take every morning and every evening at each step, starting with step 5.</p><p><img src="data:image/jpeg;base64,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" alt="" width="841" height="503" vspace="0" hspace="0" border="0" style="width:841px;height:503px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_5" o:spid="_x0000_i1026" type="#_x0000_t75" alt="PIL Titration chart 2 26-Jan 2016"
 style='width:451.8pt;height:276pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/4/msohtmlclip1/01/clip_image003.jpg"
  o:title="PIL Titration chart 2 26-Jan 2016"/>
</v:shape><![endif]--></p><p>You will receive the titration pack which contains a titration guide and Patient Leaflet. The titration guide is providing information on the titration process and is allowing you to record the number of tablets you take every day.</p><p>&nbsp;</p><p>Remember to record the number of tablets you take every day in your titration diary. The titration steps usually last about 1&nbsp;week. If your doctor instructs you to prolong each titration step longer than 1&nbsp;week, there are additional diary pages to allow you to track this. <strong>Remember to talk to your PAH doctor or nurse regularly during titration.</strong></p><p>&nbsp;</p><p><strong>Stepping down to a lower dose due to side effects</strong></p><p>&nbsp;</p><p>During titration, you may experience side effects such as headache, diarrhoea, feeling sick (nausea), being sick (vomiting), jaw pain, muscle pain, leg pain, joint pain, or reddening of the face (see section&nbsp;4). If these side effects are difficult for you to tolerate, talk to your doctor about how to manage or treat them. There are treatments available that can help relieve the side effects. For example, painkillers such as paracetamol may help treat pain and headache.</p><p>&nbsp;</p><p>If the side effects cannot be treated or do not gradually get better on the dose you are taking, your doctor may adjust your dose by reducing the number of 200&nbsp;microgram light‑yellow tablets you take by one in the morning and by one in the evening. The diagram below shows stepping down to a lower dose. Do this only if instructed to do so by your doctor.</p><p><img src="data:image/jpeg;base64,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" alt="" width="787" height="407" vspace="0" hspace="0" border="0" style="width:787px;height:407px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>If your side effects are manageable after stepping down your dose, your doctor may decide that you should stay on that dose. Please see section Maintenance dose below for more information.</p><p>&nbsp;</p><p><strong>Maintenance dose</strong></p><p>&nbsp;</p><p>The highest dose that you can tolerate during titration will become your maintenance dose. Your maintenance dose is the dose you should continue to take on a regular basis.</p><p>&nbsp;</p><p>Your doctor will prescribe a suitable tablet strength for your maintenance dose. <strong>This allows you to take one tablet in the morning and one in the evening, instead of multiple tablets each time.</strong></p><p>&nbsp;</p><p>For a full description of Uptravi tablets, including colours and marking, please see section&nbsp;6 of this leaflet.</p><p>&nbsp;</p><p>Over time, your doctor may adjust your maintenance dose as needed.</p><p>&nbsp;</p><p>If, at any time, after taking the same dose for a long time, you experience side effects that you cannot tolerate or side effects that have an impact on your normal daily activities, contact your doctor as your dose may need to be reduced. The doctor may then prescribe you a lower single‑tablet strength. Please remember to dispose of unused tablets (see section&nbsp;5).</p><p>&nbsp;</p><p><strong>Take Uptravi once in the morning and once in the evening, about 12</strong><strong>&nbsp;</strong><strong>hours apart.</strong></p><p>Take the tablets with meals as you might tolerate your medicine better. The tablet coating provides protection. Swallow the tablets whole with a glass of water. Do not split, crush or chew the tablets.</p><p>&nbsp;</p><p><strong>If you take more Uptravi than you should</strong></p><p>&nbsp;</p><p>If you have taken more tablets than you have been told to take, ask your doctor for advice.</p><p>&nbsp;</p><p><strong>If you forget to take Uptravi</strong></p><p>&nbsp;</p><p>If you forget to take Uptravi, take a dose as soon as you remember, then continue to take your tablets at the usual times. If it is nearly time for your next dose (within 6&nbsp;hours before you would normally take it), you should skip the missed dose and continue to take your medicine at the usual time. <strong>Do not take a double dose to make up for a forgotten tablet.</strong></p><p>&nbsp;</p><p><strong>If you stop taking Uptravi</strong></p><p>&nbsp;</p><p>Suddenly stopping your treatment with Uptravi might lead to your symptoms getting worse. Do not stop taking Uptravi unless your doctor tells you to. Your doctor may tell you to reduce the dose gradually before stopping completely.</p><p>&nbsp;</p><p>If, for any reason, you stop taking Uptravi for more than 3&nbsp;consecutive days (if you missed 3&nbsp;morning and 3&nbsp;evening doses, or 6&nbsp;doses in a row or more), <strong>contact your doctor immediately as your dose may need to be adjusted to avoid side effects</strong>. Your doctor may decide to restart your treatment on a lower dose, gradually increasing to your previous maintenance dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. You may experience side effects not only during the titration period when your dose is being increased, but also later after taking the same dose for a long time.</p><p>&nbsp;</p><p><strong>If you experience any of these side effects: headache, diarrhoea, feeling sick (nausea), being sick (vomiting), jaw pain, muscle pain, leg pain, joint pain, or reddening of the face, that you cannot tolerate or that cannot be treated, you should contact your doctor as the dose you are taking maybe too high for you and may need to be reduced.</strong></p><p>&nbsp;</p><p><strong>Very common side effects </strong>(may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing (reddening of the face)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea and vomiting (feeling sick and being sick)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaw pain, muscle pain, joint pain, leg pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nasopharyngitis (stuffy nose)</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (low red blood cell levels)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperthyroidism (overactive thyroid gland)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension (low blood pressure)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain, including indigestion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some blood test results including those measuring blood cell counts or your thyroid function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rashes, including hives, may cause a burning or stinging sensation and skin redness</p><p>&nbsp;</p><p><strong>Uncommon side effects (</strong>may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased heart rate</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use Uptravi after the expiry date, which is stated on the carton and on the blister after &ldquo;EXP.&rdquo; The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30⁰C</p><p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is selexipag.</p><p>Uptravi 200&nbsp;microgram film‑coated tablets contain 200&nbsp;micrograms of selexipag</p><p>Uptravi 400&nbsp;microgram film‑coated tablets contain 400&nbsp;micrograms of selexipag</p><p>Uptravi 600&nbsp;microgram film‑coated tablets contain 600&nbsp;micrograms of selexipag</p><p>Uptravi 800&nbsp;microgram film‑coated tablets contain 800&nbsp;micrograms of selexipag</p><p>Uptravi 1,000&nbsp;microgram film‑coated tablets contain 1,000&nbsp;micrograms of selexipag</p><p>Uptravi 1,200&nbsp;microgram film‑coated tablets contain 1,200&nbsp;micrograms of selexipag</p><p>Uptravi 1,400&nbsp;microgram film‑coated tablets contain 1,400&nbsp;micrograms of selexipag</p><p>Uptravi 1,600&nbsp;microgram film‑coated tablets contain 1,600&nbsp;micrograms of selexipag</p><p>&nbsp;</p><p>The other ingredients are:</p><p>&nbsp;</p><p><u>Tablet core</u></p><p>Mannitol (E421)</p><p>Maize starch</p><p>Low‑substituted hydroxypropylcellulose</p><p>Hydroxypropylcellulose</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Film coating</u></p><p>Hypromellose</p><p>Propylene glycol</p><p>Titanium dioxide (E171)</p><p>Iron oxides (E172)</p><p>Carnauba wax</p><p>&nbsp;</p><p>Uptravi 200&nbsp;microgram film‑coated tablets contain iron oxide yellow (E172).</p><p>Uptravi 400&nbsp;microgram film‑coated tablets contain iron oxide red (E172).</p><p>Uptravi 600&nbsp;microgram film‑coated tablets contain iron oxide red and iron oxide black (E172).</p><p>Uptravi 800&nbsp;microgram film‑coated tablets contain iron oxide yellow and iron oxide black (E172).</p><p>Uptravi 1,000&nbsp;microgram film‑coated tablets contain iron oxide red and iron oxide yellow (E172).</p><p>Uptravi 1,200&nbsp;microgram film‑coated tablets contain iron oxide black and iron oxide red (E172).</p><p>Uptravi 1,400&nbsp;microgram film‑coated tablets contain iron oxide yellow (E172).</p><p>Uptravi 1,600&nbsp;microgram film‑coated tablets contain iron oxide black, iron oxide red and iron oxide yellow (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Uptravi 200 microgram film coated tablets: Round, light yellow, film coated tablets with “2” marked on one side.

Uptravi 400 microgram film coated tablets: Round, red, film coated tablets with “4” marked on one side.

Uptravi 600 microgram film coated tablets: Round, light violet, film coated tablets with “6” marked on one side.

Uptravi 800 microgram film coated tablets: Round, green, film coated tablets with “8” marked on one side.

Uptravi 1,000 microgram film coated tablets: Round, orange, film coated tablets with “10” marked on one side.

Uptravi 1,200 microgram film coated tablets: Round, dark violet, film coated tablets with “12” marked on one side.

Uptravi 1,400 microgram film coated tablets: Round, dark yellow, film coated tablets with “14” marked on one side.

Uptravi 1,600 microgram film coated tablets: Round, brown, film coated tablets with “16” marked on one side.

	Uptravi 200 microgram film coated tablets are supplied in blister packs of 10 or 60 tablets and 60 or 140 tablets (titration packs).
	
	Uptravi 400 microgram, 600 microgram, 800 microgram, 1,000 microgram, 1,200 microgram, 1,400 microgram, and 1,600 microgram film coated tablets are supplied in blister packs of 60 tablets.
	
	Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Janssen‑Cilag International NV</p><p>Turnhoutseweg 30</p><p>B‑2340 Beerse</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Excella GmbH &amp; Co KG,</p><p>N&uuml;rnberger Str. 12,</p><p>&nbsp;90537 Feucht,</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 19 May 2022.
To contact us, go to www.janssen.com/contact-us 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أبترافي هو دواء يحتوي على المادة الفعالة سيليكسيباج. وهو يعمل على الأوعية الدموية بطريقة مشابهة لمادة البروستاسيكلين الطبيعية، مما يساعد على استرخاءها واتساعها.</p><p>&nbsp;</p><p dir="RTL">يستخدم أبترافي للعلاج طويل المدى لارتفاع ضغط الدم الشرياني الرئوي (PAH) في المرضى البالغين الذين لم يتم التحكم لديهم بشكل كافٍ باستخدام أنواع أخرى من الأدوية المخصصة لعلاج PAH المعروفة باسم مضادات مستقبلات الإندوثيلين ومثبطات إنزيم فوسفودايستراز 5. ويمكن استخدام أبترافي بمفرده إذا كان المريض غير مرشح لهذه الأدوية.</p><p>&nbsp;</p><p dir="RTL">يعرف مرض PAH بأنه ارتفاع ضغط الدم في الأوعية الدموية التي تنقل الدم من القلب إلى الرئتين (الشرايين الرئوية)، ويعاني الأشخاص المصابين بمرض PAH من ضيق هذه الشرايين، مما يجعل القلب يعمل بجهد أكبر لضخ الدم عبرها. وقد يتسبب ذلك في شعور الأشخاص بالتعب أو الدوار أو ضيق النفس أو مواجهة أعراض أخرى.</p><p>&nbsp;</p><p dir="RTL">يوسع هذا الدواء الشرايين الرئوية ويقلل من تصلبها عن طريق محاكاة عمل مادة البروستاسيكلين الطبيعية. وبهذا يسهل على القلب ضخ الدم عبر الشرايين الرئوية. ويعمل أبترافي على تخفيف الضغط على الشرايين الرئوية و يخفف أعراض PAH و يبطئ تقدم مسار مرض PAH.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال أبترافي</strong></p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه سيليكسيباج أو أي من المكونات الأخرى في هذا الدواء (مدرجة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلة في القلب، مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف تدفق الدم إلى عضلات القلب (مرض الشريان التاجي الحاد أو الذبحة الصدرية غير المستقرة)؛ قد تشمل الأعراض ألم في الصدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية خلال آخر 6 أشهر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور القلب (فشل القلب اللاتعويضي) الذي لا يخضع لملاحظة طبية وثيقة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب الحاد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عيوب صمامات القلب (الخلقية أو المكتسبة) التي تسبب ضعف أداء القلب (لا علاقة لها بارتفاع ضغط الدم الرئوي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بسكتة دماغية خلال آخر 3 أشهر، أو أي حدث آخر كان قد قلل من وصول الدم إلى المخ (مثل النوبة الإقفارية العابرة)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول جيمفيبروزيل (دواء يستخدم لخفض مستوى الدهون [الشحوم] في الدم)</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p>&nbsp;</p><p dir="RTL">استشر طبيب PAH الخاص بك أو الممرضة قبل تناول أبترافي إذا كنت:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية لعلاج ارتفاع ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من ضغط دم منخفض مرتبط بأعراض مثل الدوار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عانيت مؤخرًا من فقدان كبير للدم أو فقدان للسوائل مثل الإسهال الشديد أو القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من مشاكل في الغدة الدرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من مشاكل حادة في الكليتين أو تخضع لغسيل كلوي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعانى أو كنت تعاني من مشاكل حادة في الكبد حيث لا يعمل بشكل صحيح</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا لاحظت أيًّا من الأعراض المذكورة أعلاه أو تغيرت حالتك، <strong>فأخبر طبيبك على الفور</strong>.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p>&nbsp;</p><p dir="RTL">لا تعط هذا الدواء للأطفال دون سن 18&nbsp;عامًا، لأن أبترافي لم يتم اختباره على الأطفال.</p><p>&nbsp;</p><p dir="RTL"><strong>المرضى كبار السن</strong></p><p>&nbsp;</p><p dir="RTL">توجد خبرة محدودة مع أبترافي في المرضى الذين تزيد أعمارهم عن 75&nbsp;عامًا. ينبغي استخدام دواء أبترافي بحذر في هذه الفئة العمرية.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وأبترافي</strong></p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ، أو أخذت مؤخرًا، أو قد تأخذ أية أدوية أخرى.</p><p dir="RTL">إن تناول أدوية أخرى قد يؤثر على طريقة عمل أبترافي.</p><p>&nbsp;</p><p dir="RTL">استشر طبيب PAH الخاص بك أو الممرضة إذا كنت تتناول أيًّا من الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جيمفيبروزيل (دواء يستخدم لخفض مستوى الدهون [الشحوم] في الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلوبدوجريل (دواء يستخدم لتثبيط حدوث الجلطات الدموية في مرض الشريان التاجي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديفيراسيروكس (دواء يستخدم لإزالة الحديد من مجرى الدم)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيريفلونوميد (دواء يستخدم لعلاج التصلب المتعدد متكرر الانتكاس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين (دواء يستخدم لعلاج بعض أشكال الصرع وآلام الأعصاب أو للمساعدة في السيطرة على اضطرابات المزاج الخطيرة عندما لا تعمل بعض الأدوية الأخرى)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فنيتوين (دواء يستخدم لعلاج الصرع)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الفالبرويك (دواء يستخدم لعلاج الصرع)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبينسيد (دواء يستخدم لعلاج النقرس)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فلوكونازول أو ريفامبيسين أو ريفابنتين (مضادات حيوية تستخدم لعلاج حالات العدوى)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p>&nbsp;</p><p dir="RTL">لا ينصح باستخدام أبترافي أثناء الحمل أو الرضاعة. إذا كنتِ سيدة يمكن أن تنجب أطفالًا، فينبغي عليكِ استخدام وسيلة فعالة لمنع الحمل أثناء تناول أبترافي. إذا كنتِ حاملاً أو ترضعين، أو تعتقدين بأنكِ قد تكونين حاملاً أو تخططين لإنجاب طفل، فاستشيري طبيبكِ للحصول على النصيحة قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p>&nbsp;</p><p dir="RTL">يمكن أن يسبب أبترافي آثارًا جانبية مثل الصداع وانخفاض ضغط الدم (انظر القسم&nbsp;4)، مما قد يؤثر على قدرتك على القيادة؛ أعراض حالتك أيضًا يمكن أن تجعلك أقل ملائمة للقيادة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن يتم وصف أبترافي من قبل طبيب من ذوي الخبرة في علاج ارتفاع ضغط الدم الشرياني الرئوي. احرص دائمًا على تناول هذا الدواء كما أخبرك الطبيب تمامًا. تأكد من طبيبك إذا &nbsp;راودك الشك أو كانت لديك أية استفسارات.</p><p dir="RTL">أخبر طبيبك إذا كنت تعاني من آثار جانبية ، فقد يوصي طبيبك بتغيير جرعة أبترافي .</p><p dir="RTL">أخبر طبيبك اذا كنت تتناول أدوية أخرى &nbsp;لأن طبيبك قد يوصي بأخد علاج أبترافي مرة واحدة يوميا فقط .</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك ضعف في الرؤية أو تعاني من أي نوع من العمى، فيمكنك الحصول على المساعدة من شخص آخر عند تناول أبترافي أثناء فترة المعايرة (عملية زيادة الجرعة تدريجياً).</p><p>&nbsp;</p><p dir="RTL"><strong>العثور على الجرعة المناسبة لك</strong></p><p>&nbsp;</p><p dir="RTL">في بداية العلاج، ستتناول أقل جرعة. وهي قرص واحد 200&nbsp;ميكروجرام <strong>في الصباح وقرص آخر 200</strong>&nbsp;<strong>ميكروجرام في المساء</strong>. مع فرق 12 ساعة. يفضل أن يبدأ العلاج في المساء. سيوجهك طبيبك بزيادة الجرعة تدريجيًا. ويسمى هذا بالمعايرة. حيث تتيح لجسمك التكيف مع الدواء الجديد. والهدف من المعايرة هو الوصول إلى أنسب جرعة. وستكون هذه هي أعلى جرعة يمكنك تحملها، والتي قد تصل إلى الحد الأقصى للجرعة البالغ 1600&nbsp;ميكروجرام في الصباح وفي المساء.</p><p>&nbsp;</p><p dir="RTL">ستحتوي العبوة الأولى من الأقراص التي تتلقاها على أقراص 200&nbsp;ميكروجرام باللون الأصفر الفاتح.</p><p dir="RTL">وسيخبرك طبيبك بزيادة الجرعة على خطوات، عادة كل أسبوع ولكن قد تكون الفترة الفاصلة بين الزيادات أطول.</p><p>&nbsp;</p><p dir="RTL">مع كل خطوة، ستضيف قرص واحد 200&nbsp;ميكروجرام لجرعتك الصباحية وقرص آخر 200&nbsp;ميكروجرام لجرعتك المسائية. <strong>يفضل</strong> <strong>تناول أول جرعة زائدة في المساء</strong>. يوضح الرسم البياني أدناه عدد الأقراص التي ينبغي تناولها <strong>كل صباح </strong>و<strong>كل مساء </strong>لأول 4&nbsp;خطوات.</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>الجرعة المبدئية</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الخطوة 4</strong></p><p><strong>الصباح:</strong> أربعة أقراص 200 ميكروجرام</p><p><strong>المساء:</strong> أربعة أقراص 200 ميكروجرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">(إجمالي الجرعة اليومية: 1600 ميكروجرام)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>قرص <strong>200 ميكروجرام</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الخطوة 3</strong></p><p><strong>الصباح:</strong> ثلاثة أقراص 200 ميكروجرام</p><p><strong>المساء:</strong> ثلاثة أقراص 200 ميكروجرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">(إجمالي الجرعة اليومية: 1200 ميكروجرام)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الخطوة 2</strong></p><p><strong>الصباح:</strong> قرصان 200 ميكروجرام</p><p><strong>المساء:</strong> قرصان 200 ميكروجرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">(إجمالي الجرعة اليومية: 800 ميكروجرام)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>الخطوة 1</strong></p><p dir="RTL"><strong>الصباح:</strong> قرص واحد 200 ميكروجرام</p><p dir="RTL"><strong>المساء:</strong> قرص واحد 200 ميكروجرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">(إجمالي الجرعة اليومية: 400 ميكروجرام)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>تدوم كل خطوة تحديد جرعة حوالي أسبوع واحد.</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا أخبرك طبيبك بزيادة الجرعة إلى أكثر من ذلك، فسوف تضيف قرص واحد 200&nbsp;ميكروجرام إلى جرعتك الصباحية وقرص واحد 200&nbsp;ميكروجرام إلى جرعتك المسائية مع كل خطوة جديدة. ينبغي تناول أول جرعة زائدة في المساء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا طلب منك طبيبك زيادة الجرعة الخاصة بك والانتقال إلى الخطوة&nbsp;5، فقد يتم ذلك عن طريق تناول قرص واحد أخضر 800&nbsp;ميكروجرام وقرص واحد أصفر فاتح 200&nbsp;ميكروجرام في الصباح وقرص واحد 800&nbsp;ميكروجرام وقرص واحد 200&nbsp;ميكروجرام في المساء.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقصى جرعة من أبترافي هي 1600&nbsp;ميكروجرام في الصباح و1600&nbsp;ميكروجرام في المساء. ومع ذلك، لن يصل كل مريض إلى هذه الجرعة، لأن المرضى المختلفين يحتاجون إلى جرعات مختلفة.</p><p>&nbsp;</p><p dir="RTL">يوضح الرسم البياني أدناه عدد الأقراص التي ينبغي تناولها <strong>كل صباح </strong>و<strong>كل مساء </strong>في كل خطوة، بدءًا من الخطوة 5.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">قرص <strong>200 ميكروجرام</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قرص <strong>800 ميكروجرام</strong></p><p dir="RTL">(يُستخدم مع الخطوات من 5 إلى 8 لتقليل عدد الأقراص المطلوبة لكل جرعة).</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الخطوة 8</strong></p><p><strong>الصباح:</strong> قرص واحد 800 وأربعة أقراص 200 ميكروجرام</p><p><strong>المساء:</strong> قرص واحد 800 وأربعة أقراص 200 ميكروجرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">(إجمالي الجرعة اليومية: 3,200 ميكروجرام)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الخطوة 7</strong></p><p><strong>الصباح:</strong> قرص واحد 800 وثلاثة أقراص 200 ميكروجرام</p><p><strong>المساء:</strong> قرص واحد 800 وثلاثة أقراص 200 ميكروجرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">(إجمالي الجرعة اليومية: 2,800 ميكروجرام)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الخطوة 6</strong></p><p><strong>الصباح:</strong> قرص واحد 800 و قرصين &nbsp;200 ميكروجرام</p><p><strong>المساء:</strong> قرص واحد 800 &nbsp;و قرصين 200 ميكروجرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">(إجمالي الجرعة اليومية: 2,400 ميكروجرام)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الخطوة 5</strong></p><p><strong>الصباح:</strong> قرص واحد 800 وقرص واحد 200 ميكروجرام</p><p><strong>المساء:</strong> قرص واحد 800 وقرص واحد 200 ميكروجرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">(إجمالي الجرعة اليومية: 2,000 ميكروجرام)</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>أعلى جرعة</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ستحصل على عبوة المعايرة والتي تحتوي أيضًا على دليل المعايرة والنشرة الطبية. يوفر دليل المعايرة معلومات حول عملية المعايرة ويسمح لك بتسجيل عدد الأقراص التي تتناولها يوميًا.</p><p>&nbsp;</p><p dir="RTL">تذكر تسجيل عدد الأقراص التي تتناولها يوميًا في مفكرة المعايرة. عادة ما تستمر خطوات المعايرة حوالي أسبوع&nbsp;واحد. إذا طلب منك طبيبك تمديد كل خطوة معايرة إلى مدة تزيد عن أسبوع واحد، ستجد صفحات إضافية بالمفكرة تتيح لك تتبع ذلك. <strong>تذكر استشارة طبيب </strong><strong>PAH</strong><strong> الخاص بك أو الممرضة بانتظام أثناء المعايرة.</strong></p><p>&nbsp;</p><p dir="RTL"><strong>تقليل الجرعة إلى جرعة أقل بسبب الآثار الجانبية</strong></p><p>&nbsp;</p><p dir="RTL">قد تواجه أثناء المعايرة آثارًا جانبية مثل الصداع أو الإسهال أو الشعور بالرغبة في القيء (الغثيان) أو القيء أو آلام الفك أو ألم في العضلات أو ألم بالساق أو ألم بالمفاصل أو احمرار الوجه (انظر القسم&nbsp;4). إذا كنت لا تستطيع تحمل هذه الآثار الجانبية، فاستشر طبيبك بشأن كيفية التعامل معها أو علاجها. توجد علاجات متاحة يمكنها المساعدة في تخفيف الآثار الجانبية. على سبيل المثال، المسكنات مثل باراسيتامول يمكنه علاج الألم والصداع.</p><p>&nbsp;</p><p dir="RTL">إذا تعذر علاج الآثار الجانبية أو لم تتحسن تدريجيًا على الجرعة التي تتناولها، فقد يقوم طبيبك بتعديل جرعتك عن طريق تقليل عدد الأقراص 200&nbsp;ميكروجرام ذات اللون الأصفر الفاتح التي تتناولها بمقدار قرص واحد في الصباح وآخر في المساء. يوضح الرسم البياني أدناه تقليل الجرعة إلى جرعة أقل. قم بذلك فقط إذا طلب منك الطبيب ذلك.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>عودة إلى الخطوة 5</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>قم بتقليل الجرعة إذا لم تتمكن من تحمل الأعراض الجانبية</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>تقليل الجرعة</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>زيادة الجرعة</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>البداية</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الخطوة 6</strong></p><p>يتمثل الهدف في الوصول إلى أعلى جرعة ذات أعراض جانبية يمكنك تحملها</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الخطوة 2-5</strong></p><p>قم بزيادة جرعتك كل أسبوع تقريبًا بإضافة قرص 200 ميكروجرام إلى جرعتك الصباحية والمسائية</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>الخطوة 1</strong><br /><strong>الصباح: </strong>قرص واحد 200 ميكروجرام</p><p dir="RTL"><strong>المساء: </strong>قرص واحد 200 ميكروجرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">(إجمالي الجرعة اليومية: 400 ميكروجرام)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">إذا أمكن التحكم في آثارك الجانبية بعد تقليل الجرعة، فقد يقرر طبيبك أنه ينبغي عليك الاستمرار على هذه الجرعة. يرجى الاطلاع على قسم جرعة المداومة أدناه للحصول على مزيد من المعلومات.</p><p>&nbsp;</p><p dir="RTL"><strong>جرعة المداومة</strong></p><p>&nbsp;</p><p dir="RTL">أعلى جرعة يمكنك تحملها أثناء المعايرة ستصبح جرعة المداومة الخاصة بك. جرعة المداومة الخاصة بك هي الجرعة التي ينبغي عليك الاستمرار عليها بانتظام.</p><p>&nbsp;</p><p dir="RTL">سيصف طبيبك تركيز قرص مناسب لجرعة المداومة الخاصة بك. <strong>يتيح لك ذلك تناول قرص واحد في الصباح وآخر في المساء، بدلًا من تناول عدة أقراص في كل مرة.</strong></p><p>&nbsp;</p><p dir="RTL">للحصول على وصف كامل لأقراص أبترافي، بما في ذلك الألوان والعلامات، يرجى الاطلاع على القسم 6&nbsp;من هذه النشرة.</p><p>&nbsp;</p><p dir="RTL">قد يقوم طبيبك، بمرور الوقت، بتعديل جرعة المداومة الخاصة بك حسب الحاجة.</p><p>&nbsp;</p><p dir="RTL">إذا واجهت، في أي وقت، بعد تناول نفس الجرعة لفترة طويلة، آثارًا جانبية لا يمكنك تحملها أو آثار جانبية لها تأثير على أنشطتك اليومية العادية، فاتصل بطبيبك لأنك قد تحتاج إلى تقليل الجرعة. وقد يصف لك الطبيب بعد ذلك تركيز أقل ذي قرص واحد. يرجى تذكر التخلص من الأقراص غير المستخدمة (انظر القسم&nbsp;5).</p><p>&nbsp;</p><p dir="RTL"><strong>تناول أبترافي مرة واحدة في الصباح ومرة واحدة في المساء، بفارق زمني حوالي 12&nbsp;ساعة بينهما.</strong></p><p dir="RTL">تناول الأقراص مع الوجبات لأنك قد تتحمل الدواء بشكل أفضل. المادة المغلفة للقرص توفر الحماية . ابلع الأقراص بأكملها مع كوب من الماء. لا تمضغ الأقراص أو تسحقها أو تقسّمها.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة أكبر من الجرعة المقررة من أبترافي</strong></p><p>&nbsp;</p><p dir="RTL">إذا تناولت جرعة أكبر من الجرعة التي حُددت لحالتك، فاستشر طبيبك.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول دواء أبترافي</strong></p><p>&nbsp;</p><p dir="RTL">إذا نسيت أن تتناول دواء أبترافي، فتناول جرعتك وقتما تتذكرها، ثم استمر في تناول الأقراص في المواعيد المعتادة. إذا حان وقت الجرعة التالية تقريبًا (خلال 6&nbsp;ساعات قبل تناولها عادة)، ينبغي عليك تجاهل الجرعة الفائتة ومواصلة تناول الدواء في الوقت المعتاد. <strong>لا تتناول جرعة مضاعفة لتعويض قرص منسي.</strong></p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول أبترافي</strong></p><p>&nbsp;</p><p dir="RTL">قد يؤدي التوقف المفاجئ عن العلاج بدواء أبترافي إلى زيادة حدة الأعراض عليك، فلا تتوقف عن تناول دواء أبترافي ما لم يخبرك الطبيب المعالج بذلك. فقد يطلب الطبيب تقليل الجرعة تدريجيًا قبل إيقاف العلاج تمامًا.</p><p>&nbsp;</p><p dir="RTL">إذا توقفت لأي سبب من الأسباب عن تناول أبترافي لأكثر من 3&nbsp;أيام متتالية (إذا فاتتك 3&nbsp;جرعات صباحية و3&nbsp;جرعات مسائية، أو 6&nbsp;جرعات متتالية أو أكثر)، <strong>فاتصل بطبيبك على الفور حيث قد يلزم تعديل جرعتك لتجنب حدوث آثار جانبية</strong>. قد يقرر طبيبك إعادة بدء العلاج بجرعة أقل، وزيادتها تدريجيًا إلى جرعة المداومة السابقة الخاصة بك.</p><p>&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل طبيبك أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب &nbsp;هذا الدواء آثارًا جانبية قد لا تحدث للجميع. قد تواجه آثارًا جانبية ليس فقط خلال فترة المعايرة عند زيادة الجرعة، ولكن أيضًا في وقت لاحق بعد تناول الجرعة نفسها لفترة طويلة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا واجهت أيًا من هذه الآثار الجانبية: الصداع أو الإسهال أو الشعور بالرغبة في القيء (الغثيان) أو القيء أو آلام الفك أو ألم في العضلات أو ألم بالساق أو ألم بالمفاصل أو احمرار الوجه لا يمكنك علاجها أو لا يمكن تحملها، فينبغي عليك الاتصال بطبيبك لأن الجرعة التي تتناولها ربما تكون عالية جدًا بالنسبة لك وقد تحتاج إلى تقليلها.</strong></p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا </strong>(قد تؤثر على أكثر من 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الوجه</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان والقيء (الشعور بالغثيان والقيء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الفك، آلام في العضلات، آلام بالمفاصل، آلام بالساق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البلعوم الأنفي (انسداد الأنف)</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة</strong> (قد تؤثر على 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأنيميا (انخفاض مستويات خلايا الدم الحمراء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خسارة الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة، ، بما في ذلك عسر الهضم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في بعض نتائج تحليل الدم بما في ذلك تلك التي تقيس أعداد خلايا الدم أو وظائف الغدة الدرقية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، بما في ذلك الشرى، قد يسبب إحساسًا بالحرقة أو اللسع واحمرار الجلد</p><p>&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة (</strong>قد تؤثر على 1 من كل 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدل ضربات القلب</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو الممرضة.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم أبترافي بعد انتهاء تاريخ الصلاحية المذكور على العبوة الكرتون وعلى شريط البليستر بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30 درجة مئوية.</p><p>&nbsp;</p><p dir="RTL">لا توجد متطلبات خاصة للتخلص من الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات دواء أبترافي</strong></p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي سيليكسيباج.</p><p dir="RTL">تحتوي أقراص أبترافي 200&nbsp;ميكروجرام المغلفة بطبقة رقيقة على 200&nbsp;ميكروجرام من مادة سيليكسيباج</p><p dir="RTL">تحتوي أقراص أبترافي 400&nbsp;ميكروجرام المغلفة بطبقة رقيقة على 400&nbsp;ميكروجرام من مادة سيليكسيباج</p><p dir="RTL">تحتوي أقراص أبترافي 600&nbsp;ميكروجرام المغلفة بطبقة رقيقة على 600&nbsp;ميكروجرام من مادة سيليكسيباج</p><p dir="RTL">تحتوي أقراص أبترافي 800&nbsp;ميكروجرام المغلفة بطبقة رقيقة على 800&nbsp;ميكروجرام من مادة سيليكسيباج</p><p dir="RTL">تحتوي أقراص أبترافي 1000&nbsp;ميكروجرام المغلفة بطبقة رقيقة على 1000&nbsp;ميكروجرام من مادة سيليكسيباج</p><p dir="RTL">تحتوي أقراص أبترافي 1200&nbsp;ميكروجرام المغلفة بطبقة رقيقة على 1200&nbsp;ميكروجرام من مادة سيليكسيباج</p><p dir="RTL">تحتوي أقراص أبترافي 1400&nbsp;ميكروجرام المغلفة بطبقة رقيقة على 1400&nbsp;ميكروجرام من مادة سيليكسيباج</p><p dir="RTL">تحتوي أقراص أبترافي 1600&nbsp;ميكروجرام المغلفة بطبقة رقيقة على 1600&nbsp;ميكروجرام من مادة سيليكسيباج</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المادة الأساسية للقرص:</u></p><p dir="RTL">مانيتول (E421)</p><p dir="RTL">نشا الذرة</p><p dir="RTL">هيدروكسي بروبيل سيلولوز منخفض الاستبدال</p><p dir="RTL">هيدروكسي بروبيل السيلولوز</p><p dir="RTL">ستيرات الماغنسيوم</p><p>&nbsp;</p><p dir="RTL"><u>المادة الرقيقة المغلفة:</u></p><p dir="RTL">هيبروميلوز</p><p dir="RTL">بروبيلين جليكول</p><p dir="RTL">ثاني أكسيد التيتانيوم (E171)</p><p dir="RTL">&nbsp;أكاسيد الحديد (E172).</p><p dir="RTL">شمع الكارنوبا</p><p dir="RTL">تحتوي أقراص أبترافي 200&nbsp;ميكروجرام المغلفة بطبقة رقيقة على أكسيد الحديد الأصفر (E172).</p><p dir="RTL">تحتوي أقراص أبترافي 400&nbsp;ميكروجرام المغلفة بطبقة رقيقة على أكسيد الحديد الأحمر (E172).</p><p dir="RTL">تحتوي أقراص أبترافي 600&nbsp;ميكروجرام المغلفة بطبقة رقيقة على أكسيد الحديد الأحمر وأكسيد الحديد الأسود (E172).</p><p dir="RTL">تحتوي أقراص أبترافي 800&nbsp;ميكروجرام المغلفة بطبقة رقيقة على أكسيد الحديد الأصفر وأكسيد الحديد الأسود (E172).</p><p dir="RTL">تحتوي أقراص أبترافي 1000&nbsp;ميكروجرام المغلفة بطبقة رقيقة على أكسيد الحديد الأحمر وأكسيد الحديد الأصفر (E172).</p><p dir="RTL">تحتوي أقراص أبترافي 1200&nbsp;ميكروجرام المغلفة بطبقة رقيقة على أكسيد الحديد الأسود وأكسيد الحديد الأحمر (E172).</p><p dir="RTL">تحتوي أقراص أبترافي 1400&nbsp;ميكروجرام المغلفة بطبقة رقيقة على أكسيد الحديد الأصفر (E172).</p><p dir="RTL">تحتوي أقراص أبترافي 1600&nbsp;ميكروجرام المغلفة بطبقة رقيقة على أكسيد الحديد الأسود وأكسيد الحديد الأحمر وأكسيد الحديد الأصفر (E172).</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل دواء أبترافي ومحتويات العبوة</strong></p><p>&nbsp;</p><p dir="RTL">أبترافي 200&nbsp;ميكروجرام أقراص مغلفة بطبقة رقيقة: أقراص مستديرة ذات لون أصفر فاتح مغلفة بطبقة رقيقة عليها علامة &quot;2&quot; على جانب واحد.</p><p>&nbsp;</p><p dir="RTL">أبترافي 400&nbsp;ميكروجرام أقراص مغلفة بطبقة رقيقة: أقراص مستديرة ذات لون أحمر مغلفة بطبقة رقيقة عليها علامة &quot;4&quot; على جانب واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبترافي 600&nbsp;ميكروجرام أقراص مغلفة بطبقة رقيقة: أقراص مستديرة ذات لون بنفسجي فاتح مغلفة بطبقة رقيقة عليها علامة &quot;6&quot; على جانب واحد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبترافي 800&nbsp;ميكروجرام أقراص مغلفة بطبقة رقيقة: أقراص مستديرة ذات لون أخضر مغلفة بطبقة رقيقة عليها علامة &quot;8&quot; على جانب واحد.</p><p>&nbsp;</p><p dir="RTL">أبترافي 1000&nbsp;ميكروجرام أقراص مغلفة بطبقة رقيقة: أقراص مستديرة ذات لون برتقالي مغلفة بطبقة رقيقة عليها علامة &quot;10&quot; على جانب واحد.</p><p>&nbsp;</p><p dir="RTL">أبترافي 1200&nbsp;ميكروجرام أقراص مغلفة بطبقة رقيقة: أقراص مستديرة ذات لون بنفسجي داكن مغلفة بطبقة رقيقة عليها علامة &quot;12&quot; على جانب واحد.</p><p>&nbsp;</p><p dir="RTL">أبترافي 1400&nbsp;ميكروجرام أقراص مغلفة بطبقة رقيقة: أقراص مستديرة ذات لون أصفر داكن مغلفة بطبقة رقيقة عليها علامة &quot;14&quot; على جانب واحد.</p><p>&nbsp;</p><p dir="RTL">أبترافي 1600&nbsp;ميكروجرام أقراص مغلفة بطبقة رقيقة: أقراص مستديرة ذات لون بني مغلفة بطبقة رقيقة عليها علامة &quot;16&quot; على جانب واحد.</p><p>&nbsp;</p><p dir="RTL">يتم توفير أقراص أبترافي 200&nbsp;ميكروجرام المغلفة بطبقة رقيقة في عبوات بها أشرطة تحتوي على 10 أو 60&nbsp;قرص و60 أو 140&nbsp;قرص (عبوات المعايرة).</p><p>&nbsp;</p><p dir="RTL">يتم توفير أقراص أبترافي 400 ميكروجرام و 600 ميكروجرام و800 ميكروجرام و1000 ميكروجرام و1200 ميكروجرام و1400 ميكروجرام و1600 المغلفة بطبقة رقيقة في عبوات بها أشرطة مكونة من 60&nbsp;قرصًا.</p><p>&nbsp;</p><p dir="RTL">يمكن عدم طرح جميع الأحجام في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل الرخصة التسويقية </strong></p><p dir="RTL">جانسن سيلاج انترناشونال إن في،</p><p dir="RTL">&nbsp;ترنهوتسويج- 30،</p><p dir="RTL">&nbsp;بي-2340 بيرس،</p><p dir="RTL">&nbsp;بلجيكا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنّعة </strong></p><p dir="RTL">أكسيلا جي ام بي اتش اند كو كي جي،</p><p dir="RTL">12 نورنبرجر،&nbsp;</p><p dir="RTL">90537 فيوشت ،&nbsp;</p><p dir="RTL">ألمانيا&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت آخر مراجعة لهذه النشرة في  19 مايو 2022. 
	للتواصل معنا، تفضل بزيارة الموقع الإلكتروني www.janssen.com/contact-us
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Uptravi 200 microgram film-coated tablets.
Uptravi 400 microgram film coated tablets
Uptravi 600 microgram film-coated tablets.
Uptravi 800 microgram film coated tablets
Uptravi 1,000 microgram film-coated tablets. 
Uptravi 1,200 microgram film-coated tablets. 
Uptravi 1,400 microgram film-coated tablets. 
Uptravi 1,600 microgram film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Uptravi 200 microgram film-coated tablets
Each film-coated tablet contains 200 micrograms of selexipag.

Uptravi 400 microgram film coated tablets

Each film coated tablet contains 400 micrograms of selexipag 

Uptravi 600 microgram film-coated tablets
Each film-coated tablet contains 600 micrograms of selexipag.

Uptravi 800 microgram film coated tablets

Each film coated tablet contains 800 micrograms of selexipag.

Uptravi 1,000 microgram film-coated tablets
Each film-coated tablet contains 1,000 micrograms of selexipag.

Uptravi 1,200 microgram film-coated tablets
Each film-coated tablet contains 1,200 micrograms of selexipag.

Uptravi 1,400 microgram film-coated tablets
Each film-coated tablet contains 1,400 micrograms of selexipag.

Uptravi 1,600 microgram film-coated tablets
Each film-coated tablet contains 1,600 micrograms of selexipag. For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet

Uptravi 200 microgram film coated tablets
Round, 7.3 mm diameter, light yellow, film coated tablets,with “2” debossed on one side.

Uptravi 400 microgram film coated tablets
Round, 7.3 mm diameter, red, film coated tablets with “4” debossed on one side.

Uptravi 600 microgram film coated tablets
Round, 7.3 mm diameter, light violet, film coated tablets with “6” debossed on one side.

Uptravi 800 microgram film coated tablets
Round, 7.3 mm diameter, green, film coated tablets with “8” debossed on one side.

Uptravi 1,000 microgram film coated tablets
Round, 7.3 mm diameter, orange, film coated tablets with “10” debossed on one side.

Uptravi 1,200 microgram film coated tablets
Round, 7.3 mm diameter, dark violet, film coated tablets with “12” debossed on one side.

Uptravi 1,400 microgram film coated tablets
Round, 7.3 mm diameter, dark yellow, film coated tablets with “14” debossed on one side.

Uptravi 1,600 microgram film coated tablets
Round, 7.3 mm diameter, brown, film coated tablets with “16” debossed on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II&ndash;III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.</p><p>&nbsp;</p><p>Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should only be initiated and monitored by a physician experienced in the treatment of PAH.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em>Individualised dose titration</em></p><p>Each patient should be up‑titrated to the highest individually tolerated dose, which can range from 200&nbsp;micrograms given twice daily to 1,600&nbsp;micrograms given twice daily (individualised maintenance dose).</p><p>&nbsp;</p><p>The recommended starting dose is 200&nbsp;micrograms given twice daily, approximately 12&nbsp;hours apart. The dose is increased in increments of 200&nbsp;micrograms given twice daily, usually at weekly intervals. At the beginning of treatment and at each up‑titration step it is recommended to take the first dose in the evening. During dose titration some adverse reactions, reflecting the mode of action of selexipag (such as headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia, and flushing), may occur. They are usually transient or manageable with symptomatic treatment (see section&nbsp;4.8). However, if a patient reaches a dose that cannot be tolerated, the dose should be reduced to the previous dose level.</p><p>&nbsp;</p><p>In patients in whom up‑titration was limited by reasons other than adverse reactions reflecting the mode of action of selexipag, a second attempt to continue up‑titration to the highest individually tolerated dose up to a maximum dose of 1,600&nbsp;micrograms twice daily may be considered.</p><p>&nbsp;</p><p><em>Individualised maintenance dose</em></p><p>The highest tolerated dose reached during dose titration should be maintained. If the therapy over time is less tolerated at a given dose, symptomatic treatment and/or a dose reduction to the next lower dose should be considered.</p><p>&nbsp;</p><p><em>Interruptions and discontinuations</em></p><p>If a dose is missed, it should be taken as soon as possible. The missed dose should not be taken if the next scheduled dose is within approximately 6&nbsp;hours.</p><p>&nbsp;</p><p>If treatment is missed for 3&nbsp;days or more, Uptravi should be restarted at a lower dose and then up‑titrated.</p><p>&nbsp;</p><p>There is limited experience with abrupt discontinuation of selexipag in patients with PAH. No evidence for acute rebound has been observed.</p><p>&nbsp;</p><p>However, if the decision to withdraw Uptravi is taken, it should be done gradually while an alternative therapy is introduced.</p><p>&nbsp;</p><p><em>Dose adjustment with co-administration of moderate CYP2C8 inhibitors</em></p><p>When co-administered with moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox and teriflunomide), reduce the dosing of Uptravi to once daily. If the therapy is not tolerated at a given dose, symptomatic treatment and/or a dose reduction to the next lower dose should be considered. Revert to twice daily dosing frequency of Uptravi when co-administration of moderate CYP2C8 inhibitor is stopped (see section 4.5).</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly (&ge;</em><em>&nbsp;65</em><em>&nbsp;years)</em></p><p>No adjustment to the dose regimen is needed in elderly people (see section&nbsp;5.2). There is limited clinical experience in patients over the age of 75&nbsp;years, therefore Uptravi should be used with caution in this population (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Hepatic impairment</p><p>Selexipag should not be administered in patients with severe liver impairment (Child‑Pugh class&nbsp;C; see section&nbsp;4.4). For patients with moderate hepatic impairment (Child‑Pugh class&nbsp;B), the starting dose of treatment should be 200&nbsp;micrograms once daily and increased at weekly intervals by increments of 200&nbsp;micrograms given once daily until adverse reactions, reflecting the mode of action of selexipag, that cannot be tolerated or medically managed are experienced. No adjustment to the dose regimen is needed in patients with mild hepatic impairment (Child‑Pugh class&nbsp;A).</p><p>&nbsp;</p><p>Renal impairment</p><p>No adjustment to the dose regimen is needed in patients with mild or moderate renal impairment. No change in starting dose is required in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] &lt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>); dose titration should be done with caution in these patients (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of selexipag in children aged 0 to less than 18&nbsp;years have not yet been established. No data are available. Administration of selexipag in the paediatric population is not recommended. Animal studies indicated an increased risk of intussusception, but the clinical relevance of these findings is unknown (see section&nbsp;5.3).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral use.</p><p>&nbsp;</p><p>The film‑coated tablets are to be taken orally in the morning and in the evening. To improve tolerability, it is recommended to take Uptravi with food and, at the beginning of each up‑titration phase, to take the first increased dose in the evening.</p><p>&nbsp;</p><p>The tablets should not be split, crushed or chewed, and are to be swallowed with water.</p><p>&nbsp;</p><p>Patients who have poor vision or are blind must be instructed to get assistance from another person when taking Uptravi during the titration period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
•	Severe coronary heart disease or unstable angina.
•	Myocardial infarction within the last 6 months.
•	Decompensated cardiac failure if not under close medical supervision.
•	Severe arrhythmias.
•	Cerebrovascular events (e.g., transient ischaemic attack, stroke) within the last 3 months.
•	Congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension.
•	Concomitant use of strong inhibitors of CYP2C8 (e.g., gemfibrozil; see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypotension</u></p><p>&nbsp;</p><p>Selexipag has vasodilatory properties that may result in lowering of blood pressure. Before prescribing Uptravi, physicians should carefully consider whether patients with certain underlying conditions could be adversely affected by vasodilatory effects (e.g., patients on antihypertensive therapy or with resting hypotension, hypovolaemia, severe left ventricular outflow obstruction or autonomic dysfunction) (see section 4.8).</p><p>&nbsp;</p><p><u>Hyperthyroidism</u></p><p>&nbsp;</p><p>Hyperthyroidism has been observed with Uptravi. Thyroid function tests are recommended as clinically indicated in the presence of signs or symptoms of hyperthyroidism (see section 4.8).</p><p>&nbsp;</p><p><u>Pulmonary veno</u><u>‑occlusive disease</u></p><p>&nbsp;</p><p>Cases of pulmonary oedema have been reported with vasodilators (mainly prostacyclins) when used in patients with pulmonary veno‑occlusive disease. Consequently, if signs of pulmonary oedema occur when Uptravi is administered in patients with PAH, the possibility of pulmonary veno‑occlusive disease should be considered. If confirmed, treatment is to be discontinued.</p><p>&nbsp;</p><p><u>Elderly (&ge;</u><u>&nbsp;65</u><u>&nbsp;years)</u></p><p>&nbsp;</p><p>There is limited clinical experience with selexipag in patients over the age of 75&nbsp;years, therefore, Uptravi should be used with caution in this population (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>There is no clinical experience with selexipag in patients with severe liver impairment (Child‑Pugh class&nbsp;C), therefore treatment should not be administered in these patients. The exposure to selexipag and its active metabolite is increased in subjects with moderate hepatic impairment (Child‑Pugh class&nbsp;B; see section&nbsp;5.2). In patients with moderate hepatic impairment, Uptravi should be dosed once daily (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>In patients with severe renal impairment (eGFR &lt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), caution should be exercised during dose titration. There is no experience with Uptravi in patients undergoing dialysis (see section&nbsp;5.2), therefore Uptravi should not be used in these patients.</p><p>&nbsp;</p><p><u>Women of childbearing potential</u></p><p><u>&nbsp;</u></p><p>Women of childbearing potential should practise effective contraception while taking selexipag (see section 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of other medicinal products on selexipag</u></p><p>&nbsp;</p><p>Selexipag is hydrolysed to its active metabolite by carboxylesterases (see section&nbsp;5.2). Selexipag and its active metabolite both undergo oxidative metabolism mainly by CYP2C8 and to a smaller extent by CYP3A4. The glucuronidation of the active metabolite is catalysed by UGT1A3 and UGT2B7. Selexipag and its active metabolite are substrates of OATP1B1 and OATP1B3. Selexipag is a weak substrate of the P‑gp efflux pump. The active metabolite is a weak substrate of the breast cancer resistance protein (BCRP).</p><p>&nbsp;</p><p>The pharmacokinetics of selexipag and its active metabolite are not affected by warfarin.</p><p>&nbsp;</p><p><em>Inhibitors of CYP2C8</em></p><p>In the presence of 600 mg gemfibrozil, twice a day, a strong inhibitor of CYP2C8, exposure to selexipag increased approximately 2-fold, whereas exposure to the active metabolite, the major contributor to efficacy, increased approximately 11-fold. Concomitant administration of Uptravi with strong inhibitors of CYP2C8 (e.g., gemfibrozil) is contraindicated (see section&nbsp;4.3).</p><p>&nbsp;</p><p>Concomitant administration of Uptravi with clopidogrel (loading dose of 300 mg or maintenance dose of 75 mg once a day), a moderate inhibitor of CYP2C8, had no relevant effect on the exposure to selexipag but increased the exposure to the active metabolite approximately 2.2 and 2.7-fold following loading dose and maintenance dose, respectively. Dosing frequency of Uptravi should be reduced to once daily when co-administered with moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox, teriflunomide). Dosing frequency of Uptravi should be reverted to twice daily when co-administration of moderate CYP2C8 inhibitor is stopped (see section 4.2).</p><p>&nbsp;</p><p><em>Inducers of CYP2C8</em></p><p>In the presence of 600 mg rifampicin, once a day, an inducer of CYP2C8 (and UGT enzymes), the exposure to selexipag did not change, whereas exposure to the active metabolite was reduced by half. Dose adjustment of selexipag may be required with concomitant administration of inducers of CYP2C8 (e.g., rifampicin, carbamazepine, phenytoin).</p><p>&nbsp;</p><p><em>Inhibitors of UGT1A3 and UGT2B7</em></p><p>The effect of strong inhibitors of UGT1A3 and UGT2B7 (valproic acid, probenecid, and fluconazole) on the exposure to selexipag and its active metabolite has not been studied. Caution is required when administering these medicinal products concomitantly with Uptravi. A potential pharmacokinetic interaction with strong inhibitors of UGT1A3 and UGT2B7 cannot be excluded.</p><p>&nbsp;</p><p><em>Inhibitors and inducers of CYP3A4</em></p><p>In the presence of 400&nbsp;mg/100&nbsp;mg lopinavir/ritonavir twice daily, a strong CYP3A4 inhibitor, exposure to selexipag increased approximately 2‑fold, whereas the exposure to the active metabolite of selexipag did not change. Given the 37‑fold higher potency of the active metabolite, this effect is not clinically relevant. Since a strong inhibitor of CYP3A4 did not affect the pharmacokinetics of the active metabolite, indicating that the CYP3A4 pathway is not important in the elimination of the active metabolite, no effect of inducers of CYP3A4 on the pharmacokinetics of the active metabolite is expected.</p><p>&nbsp;</p><p><em>PAH</em><em>‑specific therapies</em></p><p>In the Phase 3 placebo‑controlled trial in patients with PAH, the use of selexipag in combination with both an ERA and a PDE‑5 inhibitor resulted in a 30% lower exposure to the active metabolite.</p><p>&nbsp;</p><p><em>Transporter inhibitors (lopinavir/ritonavir)</em></p><p>In the presence of 400&nbsp;mg/100&nbsp;mg lopinavir/ritonavir twice daily, a strong OATP (OATP1B1 and OATP1B3) and P‑gp inhibitor, exposure to selexipag increased approximately 2‑fold, whereas the exposure to the active metabolite of selexipag did not change. Given that the majority of the pharmacological effect is driven by the active metabolite, this effect is not clinically relevant.</p><p>&nbsp;</p><p><u>Effect of selexipag on other medicinal products</u></p><p>&nbsp;</p><p>Selexipag and its active metabolite do not inhibit or induce cytochrome P450 enzymes and transport proteins at clinically relevant concentrations.</p><p>&nbsp;</p><p><em>Anticoagulants or inhibitors of platelet aggregation</em></p><p>Selexipag is an inhibitor of platelet aggregation in vitro. In the Phase 3 placebo‑controlled study in patients with PAH, no increased risk of bleeding was detected with selexipag compared to placebo, including when selexipag was administered with anticoagulants (such as heparin, coumarin‑type anticoagulants) or inhibitors of platelet aggregation. In a study in healthy subjects, selexipag (400&nbsp;micrograms twice daily) did not alter the exposure to S‑warfarin (CYP2C9 substrate) or R‑warfarin (CYP3A4 substrate) after a single dose of 20&nbsp;mg warfarin. Selexipag did not influence the pharmacodynamic effect of warfarin on the international normalised ratio.</p><p>&nbsp;</p><p><em>Midazolam</em></p><p>At steady state after up-titration to 1,600&nbsp;micrograms selexipag twice a day, no clinically relevant change in exposure to midazolam, a sensitive intestinal and hepatic CYP3A4 substrate, or its metabolite, 1‑hydroxymidazolam, was observed. Concomitant administration of selexipag with CYP3A4 substrates does not require dose adjustment.</p><p>&nbsp;</p><p><em>Hormonal contraceptives</em></p><p>Specific drug‑drug interaction studies with hormonal contraceptives have not been conducted. Since selexipag did not affect the exposure to the CYP3A4 substrates midazolam and R‑warfarin or to the CYP2C9 substrate S‑warfarin, reduced efficacy of hormonal contraceptives is not expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p><u>&nbsp;</u></p><p>Women of childbearing potential should practise effective contraception while taking selexipag (see section 4.4).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no data from the use of selexipag in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Selexipag and its main metabolite showed 20- to 80‑times lower prostacyclin (IP) receptor potency <em>in&nbsp;vitro</em> for animal species used in reproductive toxicity testing compared to humans. Therefore, safety margins for potential IP&nbsp;receptor‑mediated effects on reproduction are accordingly lower than for non‑IP‑related effects (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Uptravi is not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether selexipag or its metabolites are excreted in human milk. In rats, selexipag or its metabolites are excreted in milk (see section&nbsp;5.3). A risk to the suckling child cannot be excluded. Uptravi should not be used during breast‑feeding.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no clinical data available. In rat studies, selexipag at high doses caused transient disturbances in oestrus cycles that did not affect fertility (see section&nbsp;5.3). The relevance for humans is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Uptravi has minor influence on the ability to drive and use machines. The clinical status of the patient and the adverse reaction profile of selexipag (such as headache or hypotension, see section 4.8) should be kept in mind when considering the patient&rsquo;s ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most commonly reported adverse reactions are headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia, and flushing. These reactions are more frequent during the up‑titration phase. The majority of these reactions are of mild to moderate intensity.</p><p><u>&nbsp;</u></p><p>The safety of selexipag has been evaluated in a long‑term, Phase 3 placebo‑controlled study enrolling 1,156&nbsp;patients with symptomatic PAH. The mean treatment duration was 76.4&nbsp;weeks (median 70.7&nbsp;weeks) for patients receiving selexipag versus 71.2&nbsp;weeks (median 63.7&nbsp;weeks) for patients on placebo. The exposure to selexipag was up to 4.2&nbsp;years.</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions obtained from the pivotal clinical study are tabulated below. The adverse reactions are ranked by frequency within each system organ class (SOC) and presented in order of decreasing seriousness. Frequencies are defined as very common (&ge;1/10), common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000).</p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:bottom"><p><strong>System organ class</strong></p></td><td style="vertical-align:bottom"><p><strong>Very common</strong></p></td><td style="vertical-align:bottom"><p><strong>Common</strong></p></td><td style="vertical-align:bottom"><p><strong>Uncommon</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Anaemia*</p><p>Haemoglobin decreased*</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Hyperthyroidism*</p><p>Thyroid-stimulating Hormone decreased</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Decreased appetite</p><p>Weight decrease</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache*</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Sinus tachycardia*</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Flushing*</p></td><td style="vertical-align:top"><p>Hypotension*</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Nasopharyngitis (of non-infectious origin)</p></td><td style="vertical-align:top"><p>Nasal congestion</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Gastro‑intestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea*</p><p>Vomiting*</p><p>Nausea*</p></td><td style="vertical-align:top"><p>Abdominal pain</p><p>Dyspepsia*</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Rash</p><p>Urticaria</p><p>Erythema</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Jaw pain*</p><p>Myalgia*</p><p>Arthralgia*</p><p>Pain in extremity*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top"><p><u>&nbsp;</u></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp; See section Description of selected adverse reactions.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Pharmacological effects associated with titration and maintenance treatment</em></p><p>Adverse reactions associated with the mode of action of selexipag have been observed frequently, in particular during the phase of individualised dose titration, and are tabulated below:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Prostacyclin-like associated adverse reactions</strong><strong> </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Titration</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Maintenance</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Selexipag</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>Selexipag</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>64%</p></td><td style="vertical-align:top"><p>28%</p></td><td style="vertical-align:top"><p>40%</p></td><td style="vertical-align:top"><p>20%</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>36%</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>30%</p></td><td style="vertical-align:top"><p>13%</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>29%</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>10%</p></td></tr><tr><td style="vertical-align:top"><p>Pain in jaw</p></td><td style="vertical-align:top"><p>26%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>21%</p></td><td style="vertical-align:top"><p>4%</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>15%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>8%</p></td><td style="vertical-align:top"><p>6%</p></td></tr><tr><td style="vertical-align:top"><p>Flushing</p></td><td style="vertical-align:top"><p>11%</p></td><td style="vertical-align:top"><p>4%</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>7%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>9%</p></td><td style="vertical-align:top"><p>5%</p></td></tr></tbody></table><p>&nbsp;</p><p>These effects are usually transient or manageable with symptomatic treatment. 7.5% of patients on selexipag discontinued treatment due to these adverse reactions. The approximate rate of adverse reactions that were serious was 2.3% in the selexipag group and 0.5% in the placebo group. In clinical practice, gastro‑intestinal events have been observed to respond to anti‑diarrhoeal, anti‑emetic, and anti‑nauseant medicinal products and/or medicinal products for functional gastro‑intestinal disorders. Pain‑associated events have frequently been treated with analgesics (such as paracetamol).</p><p><em>Haemoglobin decrease</em></p><p>In a Phase 3 placebo‑controlled study in patients with PAH, mean absolute changes in haemoglobin at regular visits compared to baseline ranged from -0.34 to -0.02&nbsp;g/dL in the selexipag group compared to -0.05 to 0.25&nbsp;g/dL in the placebo group. A decrease from baseline in haemoglobin concentration to below 10&nbsp;g/dL was reported in 8.6% of selexipag‑treated patients and 5.0% of placebo‑treated patients.</p><p>&nbsp;</p><p>In a phase&nbsp;3 placebo-controlled study in patients newly diagnosed with PAH, mean absolute changes in haemoglobin at regular visits compared to baseline ranged from -1.77 to -1.26&nbsp;g/dL in the triple therapy group (selexipag, macitentan, tadalafil) compared to -1.61 to -1.28&nbsp;g/dL in the double therapy group (placebo, macitentan and tadalafil). A decrease from baseline in haemoglobin concentration to below 10&nbsp;g/dL was reported in 19.0% of patients in the triple therapy group and 14.5% in the double therapy group. Anaemia was reported with very common frequency (13.4%) in the triple therapy group compared to common frequency (8.3%) in the double therapy group.</p><p>&nbsp;</p><p><em>Thyroid function tests</em></p><p>In a Phase 3 placebo‑controlled study in patients with PAH, hyperthyroidism was reported for 1.6% of patients in the selexipag group, compared to no case in the placebo group (see section&nbsp;4.4). A reduction (up to -0.3&nbsp;MU/L from a baseline median of 2.5&nbsp;MU/L) in median thyroid‑stimulating hormone was observed at most visits in the selexipag group. In the placebo group, little change in median values was apparent. There were no mean changes in triiodothyronine or thyroxine in either group.</p><p>&nbsp;</p><p><em>Increase in heart rate</em></p><p>In the Phase 3 placebo‑controlled study in patients with PAH, a transient increase in mean heart rate of 3&ndash;4&nbsp;bpm at 2&ndash;4&nbsp;hours post‑dose was observed. Electrocardiogram investigations showed sinus tachycardia in 11.3% of patients in the selexipag group compared to 8.8% in the placebo group (see section 5.1).</p><p>&nbsp;</p><p><em>Hypotension</em></p><p>In the Phase 3 placebo‑controlled study in patients with PAH, hypotension was reported for 5.8% of patients in the selexipag group compared to 3.8% in the placebo group. Mean absolute changes in systolic blood pressure at regular visits compared to baseline ranged from -2.0 to -1.5&nbsp;mmHg in the selexipag group compared to -1.3 to 0.0&nbsp;mmHg in the placebo group and in diastolic blood pressure ranged from -1.6 to -0.1&nbsp;mmHg in the selexipag group compared to -1.1 to 0.3&nbsp;mmHg in the placebo group. Systolic blood pressure decrease below 90&nbsp;mmHg was recorded for 9.7% of patients in the selexipag group compared 6.7% in the placebo group.</p><p>&nbsp;</p><p><em>Dyspepsia </em></p><p>In a phase&nbsp;3 placebo-controlled study in patients newly diagnosed with PAH, dyspepsia was reported with very common frequency (16.8%) in patients receiving triple therapy (selexipag, macitentan, tadalafil) compared to common frequency (8.3%) in patients receiving double therapy (placebo, macitentan and tadalafil).</p><p>&nbsp;</p><p><em>Long-term safety</em></p><p>Of the 1,156&nbsp;patients who participated in the pivotal study, 709 patients entered a long-term open-label extension study (330 patients who continued on selexipag from the GRIPHON study and 379 patients who received placebo in GRIPHON and crossed over to selexipag). Long-term follow up of patients treated with selexipag for a median treatment duration of 30.5 months and for a maximum of up to 103 months showed a safety profile that was similar to that observed in the pivotal clinical study described above.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p><u>To reports any side effect(s):</u></p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp; &nbsp;SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p><br /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:455.55pt;
 height:67.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Other GCC States:</strong></p><p><strong>&nbsp;</strong>&ndash; Please contact the relevant competent authority.</p><p>.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isolated cases of overdose up to 3,200&nbsp;micrograms were reported. Mild, transient nausea was the only reported consequence. In the event of overdose, supportive measures must be taken as required. Dialysis is unlikely to be effective because selexipag and its active metabolite are highly protein bound.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excluding heparin, ATC code: B01AC27</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Selexipag is a selective IP&nbsp;receptor agonist distinct from prostacyclin and its analogues. Selexipag is hydrolysed by carboxylesterases to yield its active metabolite, which is approximately 37‑fold more potent than selexipag. Selexipag and the active metabolite are high‑affinity IP&nbsp;receptor agonists with a high selectivity for the IP&nbsp;receptor versus other prostanoid receptors (EP<sub>1</sub>&ndash;EP<sub>4</sub>, DP, FP, and TP). Selectivity against EP<sub>1</sub>, EP<sub>3</sub>, FP, and TP is important because these are well‑described contractile receptors in the gastro‑intestinal tract and blood vessels. Selectivity against EP<sub>2</sub>, EP<sub>4</sub>, and DP<sub>1</sub> is important because these receptors mediate immune depressive effects.</p><p>&nbsp;</p><p>Stimulation of the IP&nbsp;receptor by selexipag and the active metabolite leads to vasodilatory as well as anti‑proliferative and anti‑fibrotic effects. Selexipag prevents cardiac and pulmonary remodelling in a rat model of PAH and causes proportional decreases in pulmonary and peripheral pressures, indicating that peripheral vasodilation reflects pulmonary pharmacodynamic efficacy. Selexipag does not cause IP&nbsp;receptor desensitisation <em>in</em><em> vitro</em> nor tachyphylaxis in a rat model.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em>Cardiac electrophysiology</em></p><p>In a thorough QT study in healthy subjects, repeated doses of 800 and 1,600&nbsp;micrograms of selexipag twice daily did not show an effect on cardiac repolarisation (QT<sub>c</sub> interval) or conduction (PR and QRS intervals) and had a mild accelerating effect on heart rate (the placebo‑corrected, baseline‑adjusted increase in heart rate reached 6&ndash;7&nbsp;bpm at 1.5 to 3&nbsp;h after dosing with 800&nbsp;micrograms selexipag and 9‑10&nbsp;bpm at the same timepoints after 1,600&nbsp;micrograms selexipag).</p><p>&nbsp;</p><p><em>Coagulation factors</em></p><p>In Phase 1 and 2 studies a slight decrease in plasma levels of von Willebrand factor (vWF) was observed with selexipag; the vWF values remained above the lower limit of the normal range.</p><p>&nbsp;</p><p><em>Pulmonary haemodynamics</em></p><p>A Phase 2 double‑blind, placebo‑controlled clinical study assessed haemodynamic variables after 17&nbsp;weeks of treatment in patients with PAH WHO FC II&ndash;III and concomitantly receiving ERAs and/or PDE‑5 inhibitors. Patients titrating selexipag to an individually tolerated dose (200&nbsp;micrograms twice daily increments up to 800&nbsp;micrograms twice daily; N&nbsp;=&nbsp;33) achieved a statistically significant mean reduction in pulmonary vascular resistance of 30.3% (95% confidence interval [CI]: -44.7%, -12.2%; p&nbsp;=&nbsp;0.0045) and an increase in cardiac index (mean treatment effect) of 0.48&nbsp;L/min/m<sup>2</sup> (95% CI: 0.13, 0.83) compared to placebo (N&nbsp;=&nbsp;10).</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em>Efficacy in patients with PAH</em></p><p>The effect of selexipag on progression of PAH was demonstrated in a multi‑centre, long‑term (maximum duration of exposure approximately 4.2&nbsp;years), double‑blind, placebo‑controlled, parallel‑group, event‑driven Phase 3 study (GRIPHON) in 1,156&nbsp;patients with symptomatic (WHO FC I&ndash;IV) PAH. Patients were randomised to either placebo (N&nbsp;=&nbsp;582) or selexipag (N&nbsp;=&nbsp;574) twice daily. The dose was increased at weekly intervals by increments of 200&nbsp;micrograms given twice daily to determine the individualised maintenance dose (200&ndash;1,600&nbsp;micrograms twice daily).</p><p>&nbsp;</p><p>The primary study endpoint was the time to first occurrence of a morbidity or mortality event up to end of treatment, defined as a composite of death (all causes); or hospitalisation for PAH; or progression of PAH resulting in need for lung transplantation or balloon atrial septostomy; or initiation of parenteral prostanoid therapy or chronic oxygen therapy; or other disease‑progression events (patients in WHO FC II or III at baseline) confirmed by a decrease in 6‑minute walk distance (6MWD) from baseline (&ge;&nbsp;15%) and worsening of WHO FC or (patients in WHO FC III or IV at baseline) confirmed by a decrease in 6MWD from baseline (&ge;&nbsp;15%) and need for additional PAH‑specific therapy.</p><p>&nbsp;</p><p>All events were confirmed by an independent adjudication committee, blinded to treatment allocation.</p><p>&nbsp;</p><p>The mean age was 48.1&nbsp;years (range 18&ndash;80&nbsp;years of age), with the majority of subjects being Caucasian (65.0%) and female (79.8%). 17.9% of patients were &ge;&nbsp;65 and 1.1% &ge;&nbsp;75&nbsp;years of age. Approximately 1%, 46%, 53%, and 1% of patients were in WHO FC I, II, III and IV, respectively, at baseline.</p><p>&nbsp;</p><p>Idiopathic or heritable PAH was the most common aetiology in the study population (58%) followed by PAH due to connective tissue disorders (29%), PAH associated with simple corrected congenital heart disease (10%), and PAH associated with other aetiologies (drugs and toxins [2%] and HIV [1%]).</p><p>&nbsp;</p><p>At baseline, the majority of enrolled patients (80%) were being treated with a stable dose of a specific therapy for PAH, either an ERA (15%) or a PDE‑5 inhibitor (32%) or both an ERA and a PDE‑5 inhibitor (33%).</p><p>&nbsp;</p><p>The overall median double‑blind treatment duration was 63.7&nbsp;weeks for the placebo group and 70.7&nbsp;weeks for the selexipag group. 23% of patients on selexipag achieved maintenance doses in the range of 200&ndash;400&nbsp;micrograms, 31% achieved doses in the range of 600&ndash;1,000&nbsp;micrograms, and 43% achieved doses in the range of 1,200&ndash;1,600&nbsp;micrograms.</p><p>&nbsp;</p><p>Treatment with selexipag 200&ndash;1,600&nbsp;micrograms twice daily resulted in a 40% reduction (hazard ratio [HR] 0.60; 99% CI:&nbsp;0.46, 0.78; one‑sided log‑rank p value &lt;&nbsp;0.0001) of the occurrence of morbidity or mortality events up to 7&nbsp;days after last dose compared to placebo (Figure 1). The beneficial effect of selexipag was primarily attributable to a reduction in hospitalisation for PAH and a reduction in other disease‑progression events (Table 1).</p><p>&nbsp;</p><p><strong>Figure 1</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan‑Meier estimates of the first morbidity‑mortality event</strong></p><p><img alt="" width="777" height="706" src="data:image/jpeg;base64,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" /></p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:101%"><tbody><tr><td colspan="7" style="vertical-align:bottom"><p><strong>Table 1</strong><strong>&nbsp;&nbsp; Summary of outcome events</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Endpoints &amp; statistics</strong></p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Patients with an event</strong><strong> </strong></p></td><td colspan="4"><p><strong>Treatment comparison: selexipag vs placebo</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Placebo (N=582)</strong></p></td><td style="vertical-align:bottom"><p><strong>Selexipag (N=574)</strong></p></td><td style="vertical-align:bottom"><p><strong>Absolute risk reduction</strong></p></td><td style="vertical-align:bottom"><p><strong>Relative risk reduction (99% CI)</strong></p></td><td style="vertical-align:bottom"><p><strong>HR</strong></p><p><strong>(99% CI)</strong></p></td><td style="vertical-align:bottom"><p><strong>p-value</strong><strong> </strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Morbidity-mortality </strong><strong>event<sup>a</sup></strong></p></td><td><p>58.3%</p></td><td><p>41.8%</p></td><td><p>16.5%</p></td><td><p>40%</p><p>(22%; 54%)</p></td><td><p>0.60</p><p>(0.46; 0.78)</p></td><td><p>&lt; 0.0001</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Hospitalisation due to </strong><strong>PAH<sup>b</sup></strong></p><p><strong>n (%)</strong></p></td><td><p>109</p><p>(18.7%)</p></td><td><p>78</p><p>(13.6%)</p></td><td><p>5.1%</p></td><td><p>33%</p><p>(2%; 54%)</p></td><td><p>0.67</p><p>(0.46; 0.98)</p></td><td><p>0.04</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Disease </strong><strong>progression<sup>b</sup></strong></p><p><strong>n (%)</strong></p></td><td><p>100</p><p>(17.2%)</p></td><td><p>38</p><p>(6.6%)</p></td><td><p>10.6%</p></td><td><p>64%</p><p>(41%; 78%)</p></td><td><p>0.36</p><p>(0.22; 0.59)</p></td><td><p>&lt; 0.0001</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>i.v./s.c.</strong></p><p><strong>Prostanoid initiation or oxygen therapy<sup>b,c</sup></strong></p><p><strong>n (%)</strong></p></td><td><p>15</p><p>(2.6%)</p></td><td><p>11</p><p>(1.9%)</p></td><td><p>0.7%</p></td><td><p>32%</p><p>(-90%; 76%)</p></td><td><p>0.68</p><p>(0.24; 1.90)</p></td><td><p>0.53</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Death up to EOT + 7</strong>&nbsp;<strong>days<sup>d</sup></strong></p><p><strong>n (%)</strong></p></td><td><p>37</p><p>(6.4%)</p></td><td><p>46</p><p>(8.0%)</p></td><td><p>-1.7%</p></td><td><p>-17%</p><p>(-107%; 34%)</p></td><td><p>1.17</p><p>(0.66; 2.07)</p></td><td><p>0.77</p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Death up to study closure<sup>d</sup></strong></p><p><strong>n (%)</strong></p></td><td><p>105</p><p>(18.0%)</p></td><td><p>100</p><p>(17.4%)</p></td><td><p>0.6%</p></td><td><p>3%</p><p>(-39%; 32%)</p></td><td><p>0.97</p><p>(0.68; 1.39)</p></td><td><p>0.42</p></td></tr><tr><td colspan="7" style="vertical-align:bottom"><p>CI = confidence interval; EOT = end of treatment; HR = hazard ratio; i.v. = intravenous; PAH = pulmonary arterial hypertension; s.c.&nbsp;=&nbsp;subcutaneous.</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; % of patients with an event at 36&nbsp;months = 100 &times; (1 &ndash; Kaplan‑Meier estimate); hazard ratio estimated using Cox&rsquo;s proportional hazard model; unstratified one‑sided log‑rank p‑value</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of patients with an event as part of the primary endpoint up to EOT + 7&nbsp;days; hazard ratio estimated using Aalen Johansen method; 2‑sided p‑value using Gray&rsquo;s test</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes &lsquo;Need for lung transplantation or atrial septostomy&rsquo; (1 patient on selexipag and 2 on placebo)</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % of patients with an event up to EOT + 7&nbsp;days or up to study closure; hazard ratio estimated using Cox&rsquo;s proportional hazard model; unstratified one‑sided log‑rank p‑value</p></td></tr></tbody></table><p>&nbsp;</p><p>The numerical increase in deaths up to end of treatment +&nbsp;7&nbsp;days but not up to study closure was further investigated by mathematical modelling, showing that the imbalance in deaths is consistent with the assumption of a neutral effect on PAH mortality and reduction of non-fatal events.</p><p>&nbsp;</p><p>The observed effect of selexipag versus placebo on the primary endpoint was consistent across individualised maintenance dose as shown by the hazard ratio for the three pre‑defined categories (0.60 for 200&ndash;400&nbsp;micrograms twice daily, 0.53 for 600&ndash;1,000&nbsp;micrograms twice daily, and 0.64 for 1,200&ndash;1,600&nbsp;micrograms twice daily), which was consistent with the overall treatment effect (0.60).</p><p>&nbsp;</p><p>The efficacy of selexipag on the primary endpoint was consistent across subgroups of age, sex, race, aetiology, geographical region, WHO FC, and as monotherapy or in combination with an ERA or a PDE‑5 inhibitor or triple combination with both an ERA and a PDE‑5 inhibitor.</p><p>&nbsp;</p><p>Time to PAH‑related death or hospitalisation for PAH was assessed as a secondary endpoint. The risk of an event for this endpoint was reduced by 30% in patients receiving selexipag compared to placebo (HR&nbsp;0.70, 99% CI:&nbsp;0.50, 0.98; one‑sided log‑rank p&nbsp;=&nbsp;0.0031). The percentages of patients with an event at Month&nbsp;36 were 28.9% and 41.3% in the selexipag and placebo groups, respectively, with an absolute risk reduction of 12.4%.</p><p>&nbsp;</p><p>The number of patients who experienced, as a first event, death due to PAH or hospitalisation for PAH up to end of treatment was 102 (17.8%) in the selexipag group and 137 (23.5%) in the placebo group. Death due to PAH as a component of the endpoint was observed in 16 (2.8%) patients on selexipag and 14 (2.4%) on placebo. Hospitalisation for PAH was observed in 86 (15.0%) patients on selexipag and 123 (21.1%) patients on placebo. Selexipag reduced the risk of hospitalisation for PAH as a first outcome event compared to placebo (HR 0.67, 99% CI: 0.46, 0.98; one‑sided log‑rank p&nbsp;=&nbsp;0.04).</p><p>&nbsp;</p><p>The total number of deaths of all causes up to study closure was 100 (17.4%) for the selexipag group and 105 (18.0%) for the placebo group (HR 0.97, 99% CI: 0.68, 1.39). The number of deaths due to PAH up to study closure was 70 (12.2%) for the selexipag group and 83 (14.3%) for the placebo group.</p><p>&nbsp;</p><p><em>Symptomatic endpoints</em></p><p>Exercise capacity was evaluated as a secondary endpoint. Median 6MWD at baseline was 376&nbsp;m (range: 90&ndash;482&nbsp;m) and 369&nbsp;m (range: 50&ndash;515&nbsp;m) in selexipag patients and placebo patients, respectively. Treatment with selexipag resulted in a placebo‑corrected median effect on 6MWD measured at trough (i.e., approximately 12&nbsp;h post‑dose) of 12&nbsp;m at Week&nbsp;26 (99% CI: 1, 24&nbsp;m; one‑sided p value&nbsp;=&nbsp;0.0027). In patients without concurrent PAH‑specific therapy, the placebo‑corrected treatment effect measured at trough was 34&nbsp;m (99% CI: 10, 63&nbsp;m).</p><p>&nbsp;</p><p>Quality of life was assessed in a subset of patients in the GRIPHON study using the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) questionnaire. There was no significant treatment effect from baseline to Week&nbsp;26.</p><p>&nbsp;</p><p><em>Long-term data in PAH</em></p><p>Patients enrolled into the pivotal study (GRIPHON) were eligible to enter a long-term open-label extension study. A total of 574&nbsp;patients were treated with selexipag in the GRIPHON study; of these, 330&nbsp;patients continued selexipag treatment in the open-label extension study. The median follow-up duration was 4.5&nbsp;years and the median exposure to selexipag was 3&nbsp;years. During the follow-up, at least one other PAH medication was added to selexipag in 28.4% of the patients. However, most of the treatment exposure (86.3%) in all of the 574&nbsp;patients was accumulated without addition of any new PAH medication. Kaplan-Meier estimates of survival of these 574&nbsp;patients across the GRIPHON and the long-term extension study at 1, 2, 5 and 7 years were 92%, 85%, 71%, and 63%, respectively. Survival at 1, 2, 5, and 7 years for 273&nbsp;patients of WHO FC II at baseline of the pivotal study were 97%, 91%, 80% and 70%, respectively, and for 294&nbsp;patients of WHO FC III at baseline were 88%, 80%, 62% and 56%, respectively. Given that additional PAH treatment was initiated in a small proportion of patients and that there was no control group in the extension study, the survival benefit of selexipag cannot be confirmed from these data.</p><p>&nbsp;</p><p><em>Initial triple combination t</em><em>reatment with </em><em>selexipag, </em><em>macitentan and tadalafil in newly diagnosed PAH patients</em></p><p>In a double blind, placebo-controlled study, a total of 247 newly diagnosed PAH patients were randomised to evaluate the treatment effect of initial triple (selexipag, macitentan and tadalafil) (N&nbsp;=&nbsp;123) versus initial double (placebo, macitentan and tadalafil) (N&nbsp;=&nbsp;124) therapy.</p><p>The primary endpoint, change from baseline in pulmonary vascular resistance (PVR) at Week&nbsp;26, did not show a statistically significant difference between the groups, while showing an improvement from baseline in both treatment groups (relative reduction by 54% in the initial triple therapy group vs 52% in the initial double therapy group).</p><p>Over a median follow-up of 2&nbsp;years, 4 (3.4%) patients in the triple therapy group and 12 (9.4%) patients in the double therapy group died.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Uptravi in one or more subsets of the paediatric population for treatment of pulmonary hypertension, (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of selexipag and its active metabolite have been studied primarily in healthy subjects. The pharmacokinetics of selexipag and the active metabolite, both after single- and multiple‑dose administration, were dose‑proportional up to a single dose of 800&nbsp;micrograms and multiple doses of up to 1,800&nbsp;micrograms twice daily. After multiple‑dose administration, steady state conditions of selexipag and the active metabolite were reached within 3&nbsp;days. No accumulation in plasma, either of parent compound or active metabolite, occurred after multiple‑dose administration.</p><p>&nbsp;</p><p>In healthy subjects, inter‑subject variability in exposure (area under the curve over a dosing interval) at steady state was 43% and 39% for selexipag and the active metabolite, respectively. Intra‑subject variability in exposure was 24% and 19% for selexipag and the active metabolite, respectively.</p><p>&nbsp;</p><p>Exposure to selexipag and the active metabolite at steady state in PAH patients and healthy subjects was similar. The pharmacokinetics of selexipag and the active metabolite in PAH patients were not influenced by the severity of the disease and did not change with time.</p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>&nbsp;</p><p>Selexipag is rapidly absorbed and is hydrolysed by carboxylesterases to its active metabolite.</p><p>&nbsp;</p><p>Maximum observed plasma concentrations of selexipag and its active metabolite after oral administration are reached within 1&ndash;3&nbsp;h and 3&ndash;4&nbsp;h, respectively.</p><p>&nbsp;</p><p>The absolute bioavailability of selexipag in humans is approximately 49%. This is most probably due to a first‑pass effect of selexipag, as plasma concentrations of the active metabolite are similar after the same oral and intravenous dose administration.</p><p>&nbsp;</p><p>In the presence of food, the exposure to selexipag after a single dose of 400&nbsp;micrograms was increased by 10% in Caucasian subjects and decreased by 15% in Japanese subjects, whereas exposure to the active metabolite was decreased by 27% (Caucasian subjects) and 12% (Japanese subjects). More subjects reported adverse events after administration in the fasted than in the fed state.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Selexipag and its active metabolite are highly bound to plasma proteins (approximately 99% in total and to the same extent to albumin and alpha1‑acid glycoprotein). The volume of distribution of selexipag at steady state is 11.7&nbsp;L.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Selexipag is hydrolysed to its active metabolite in the liver and in the intestine by carboxylesterases. Oxidative metabolism catalysed mainly by CYP2C8 and to a smaller extent by CYP3A4 leads to the formation of hydroxylated and dealkylated products. UGT1A3 and UGT2B7 are involved in the glucuronidation of the active metabolite. Except for the active metabolite, none of the circulating metabolites in human plasma exceed 3% of the total drug‑related material. Both in healthy subjects and PAH patients, after oral administration, exposure at steady state to the active metabolite is approximately 3- to 4‑fold higher than to the parent compound.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Elimination of selexipag is predominantly via metabolism with a mean terminal half‑life of 0.8&ndash;2.5&nbsp;h. The active metabolite has a half‑life of 6.2&ndash;13.5&nbsp;h. The total body clearance of selexipag is 17.9&nbsp;L/h. Excretion in healthy subjects was complete 5&nbsp;days after administration and occurred primarily via faeces (accounting for 93% of the administered dose) compared to 12% in urine.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>No clinically relevant effects of sex, race, age, or body weight on the pharmacokinetics of selexipag and its active metabolite have been observed in healthy subjects or PAH patients.</p><p><u>&nbsp;</u></p><p><u>Renal impairment</u></p><p>&nbsp;</p><p>A 1.4- to 1.7‑fold increase in exposure (maximum plasma concentration and area under the plasma concentration‑time curve) to selexipag and its active metabolite was observed in subjects with severe renal impairment (eGFR &lt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>In subjects with mild (Child‑Pugh class&nbsp;A) or moderate (Child‑Pugh class&nbsp;B) hepatic impairment, exposure to selexipag was 2- and 4‑fold higher, respectively, when compared to healthy subjects. Exposure to the active metabolite remained almost unchanged in subjects with mild hepatic impairment and was doubled in subjects with moderate hepatic impairment. Only two subjects with severe (Child-Pugh class&nbsp;C) hepatic impairment were dosed with selexipag. Exposure to selexipag and its active metabolite in these two subjects was similar to that in subjects with moderate (Child‑Pugh class&nbsp;B) hepatic impairment.</p><p>&nbsp;</p><p>Based on modelling and simulation data from a study in subjects with hepatic impairment, the exposure to selexipag at steady state in subjects with moderate hepatic impairment (Child‑Pugh class&nbsp;B) after a once‑daily regimen is predicted to be approximately 2‑fold higher than that in healthy subjects during a twice‑daily regimen. The exposure to the active metabolite at steady state in these patients during a once‑daily regimen is predicted to be similar to that in healthy subjects during a twice‑daily regimen. Subjects with severe hepatic impairment (Child‑Pugh class&nbsp;C) showed similar predicted exposure at steady state as subjects with moderate hepatic impairment during a once‑daily regimen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the repeated‑dose toxicity studies in rodents, strong blood pressure decrease as a result of exaggerated pharmacology induced transient clinical signs and reduced food consumption and body‑weight gain. In adult and juvenile dogs, intestine and bone / bone marrow were identified as the main target organs after treatment with selexipag. A delay in the closure of the femoral and/or tibial epiphyseal growth plate was observed in juvenile dogs. A no‑observed‑adverse‑effect level was not established. In juvenile dogs, intussusception due to prostacyclin‑related effects on intestinal motility was observed sporadically. Safety margins adapted for IP&nbsp;receptor potency for the active metabolite were 2‑fold (based on total exposure) in relation to human therapeutic exposure. The finding did not occur in mouse or rat toxicity studies. Because of the species‑specific sensitivity of dogs to develop intussusception, this finding is considered not relevant for adult humans.</p><p>&nbsp;</p><p>Increased bone ossification and related changes in the bone marrow in dog studies are considered to be due to the activation of EP<sub>4</sub> receptors in dogs. As human EP<sub>4</sub> receptors are not activated by selexipag or its active metabolite, this effect is species‑specific and, therefore, not relevant to humans.</p><p>&nbsp;</p><p>Selexipag and the active metabolite are not genotoxic on the basis of the overall evidence of conducted genotoxicity studies.</p><p>&nbsp;</p><p>In the 2‑year carcinogenicity studies, selexipag caused an increased incidence of thyroid adenomas in mice and Leydig cell adenomas in rats. The mechanisms are rodent‑specific. Tortuosity of retinal arterioles was noted after 2&nbsp;years of treatment only in rats. Mechanistically, the effect is considered to be induced by life‑long vasodilation and subsequent changes in ocular haemodynamics. Additional histopathological findings of selexipag were observed only at exposures sufficiently in excess of the maximum human exposure, indicating little relevance to humans.</p><p>&nbsp;</p><p>In a fertility study performed in rats, a prolongation of oestrus cycles resulting in increases in days until copulation was observed at exposures 173‑fold above therapeutic exposures (based on total exposures), the no‑observed‑effect level being 30‑fold above therapeutic exposures. Otherwise, fertility parameters were not affected.</p><p>&nbsp;</p><p>Selexipag was not teratogenic in rats and rabbits (exposure margins above therapeutic exposure of 13‑fold for selexipag and 43‑fold for the active metabolite, based on total exposure). Safety margins for potential IP&nbsp;receptor‑related effects on reproduction were 20 for fertility and 5 and 1 (based on free exposure) for embryo‑foetal development in rats and rabbits, respectively, when adapted for differences in receptor potency. In the rat pre‑/post‑natal development study, selexipag induced no effects on maternal and pup reproductive function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Mannitol (E421)</p><p>Maize starch</p><p>Low‑substituted hydroxypropyl cellulose</p><p>Hydroxypropyl cellulose</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Film coating</u></p><p><em><u>Uptravi 200</u></em><em><u>&nbsp;microgram film</u></em><em><u>‑coated tablet</u></em></p><p>Hypromellose</p><p>Propylene glycolTitanium dioxide (E171)</p><p>Iron oxide yellow (E172) Carnauba wax</p><p>&nbsp;</p><p><u>Uptravi 400</u><u>&nbsp;microgram film‑coated tablet</u></p><p>Hypromellose</p><p>Propylene glycol</p><p>Titanium dioxide (E171)</p><p>Iron oxide red (E172)</p><p>Carnauba wax</p><p>&nbsp;</p><p><u>Uptravi 600 microgram film-coated tablet</u></p><p>Hypromellose</p><p>Propylene glycolTitanium dioxide (E171)</p><p>&nbsp;</p><p>Iron oxide red (E172) Iron oxide black (E172)Carnauba wax</p><p><em><u>&nbsp;</u></em></p><p><em><u>Uptravi 800</u></em><em><u>&nbsp;microgram film‑coated tablet</u></em></p><p>Hypromellose</p><p>Propylene glycol</p><p>Titanium dioxide (E171)</p><p>Iron oxide yellow (E172)</p><p>Iron oxide black (E172)</p><p>Carnauba wax</p><p>&nbsp;</p><p><u>Uptravi 1,000 microgram film-coated tablet</u></p><p>Hypromellose,</p><p>Propylene glycol, titanium dioxide (E171)Iron oxide red (E172)</p><p>Iron oxide yellow (E172)</p><p>Carnauba wax</p><p>&nbsp;</p><p><u>Uptravi 1,200 microgram film-coated tablet</u></p><p>Hypromellose</p><p>Propylene glycolTitanium dioxide (E171) Iron oxide black (E172)Iron oxide red (E172) Carnauba wax</p><p>&nbsp;</p><p><u>Uptravi 1,400 microgram film-coated tablet</u></p><p>Hypromellose</p><p>Propylene glycol Titanium dioxide (E171)</p><p>Iron oxide yellow (E172)Carnauba wax</p><p>&nbsp;</p><p><u>Uptravi 1,600 microgram film-coated tablet</u></p><p>Hypromellose</p><p>Propylene glycol Titanium dioxide (E171)Iron oxide black (E172)Iron oxide red (E172)</p><p>Iron oxide yellow (E172)Carnauba wax</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30<sup>○</sup>C</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polyamide / aluminium / HDPE / PE with an embedded desiccant agent / HDPE blister sealed with an aluminium foil.</p><p>Each blister strip contains 10 film‑coated tablets</p><p><u>&nbsp;</u></p><p><u>Uptravi 200</u><u>&nbsp;microgram film</u><u>‑coated tablets</u></p><p><u>&nbsp;</u></p><p>Cartons of 10 or 60&nbsp;film‑coated tablets. (1 or 6 blister strips)</p><p>Cartons of 60 or 140&nbsp;film‑coated tablets (titration packs, 6 or 14 blister strips).</p><p>&nbsp;</p><p><u>Uptravi</u><u> 400&nbsp;microgram</u><u>, 600</u><u>&nbsp;microgram, 800&nbsp;</u><u>microgram, 1,000</u><u>&nbsp;</u><u>microgram, 1,200</u><u>&nbsp;</u><u>microgram, 1,400</u><u>&nbsp;</u><u>microgram, and 1,600</u><u>&nbsp;</u><u>microgram film</u><u>‑</u><u>coated tablets</u></p><p><u>&nbsp;</u></p><p>Cartons of 60&nbsp;film‑coated tablets (6 blister strips).</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen-Cilag International NV Turnhoutseweg 30
B-2340 Beerse Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                6-December-2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>